Deficient expression of MHC class II antigens in some cases of human B cell leukaemia.
Cells from the peripheral blood of patients with B cell chronic lymphocytic leukaemia (B-CLL) and acute lymphoblastic leukaemia (ALL) were examined for the expression of MHC class II antigens, using a number of monoclonal antibodies (MoAb) including L243 (anti-DR) and TU22 (anti-DQ). There was wide variation in expression of MHC class II antigens in CLL, both from patient to patient and among cells from the same individual. In a number of subjects a significant proportion of the cells had detectable levels of expression of DR antigens but not of DQ antigens. In some cases of ALL although almost all cells were MHC class II positive, DQ expression was undetectable. Differentiation of CLL cells, induced by culturing the cells with 12-0-tetradecanoyl phorbol-13-acetate (TPA), was accompanied by increases in MHC class II expression at the cell surface of up to more than 20-fold, and resulted in detectable expression of DQ antigens on greater than 90% of the cells in all the subjects studied.
D000951:Antigens, Neoplasm / Q000032:analysis*; D001402:B-Lymphocytes / Q000276:immunology; D002454:Cell Differentiation / Q000187:drug effects; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000032:analysis*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D000951:Antigens, Neoplasm; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D013755:Tetradecanoylphorbol Acetate